The Biosimilar Patent Dance, Exclusivity, And Unintended Innovation
This article was originally published in PharmAsia News
As brand firms are learning with biosimilars, laws can turn out in unexpected ways – but there may well be some pleasant surprises in the U.S. 21st Century Cures legislation.
You may also be interested in...
Study everything together and a scale-up manufacturing after preliminary efficacy results, former FDA commissioners Gottlieb and McClellan and their coauthors recommend in a pair of white papers on how the US should respond to the coronavirus pandemic.
Pink Sheet Podcast: Understanding the White House Coronavirus Treatment Announcement, US FDA Postpones Domestic Inspections, Biologics Transition Day Arrives
Pink Sheet editor and reporters discuss the pending trials of chloroquine for use against coronavirus, expanded access for remdesivir, and the official move of several biologics from regulation as drugs to regulation as biologics.
Pink Sheet Podcast: US FDA Announces Coronavirus Containment Strategy, Issues Updated Type 2 Diabetes Guidance
Pink Sheet reporter and editor consider the fall-out from the FDA decision to cancel meetings and postpone inspections due to the coronavirus pandemic, as well as look at the new cardiovascular recommendations for Type 2 diabetes drug development.